Last reviewed · How we verify

NCT05490173

The Pilot Experimental Study of the Neuroprotective Effects of Exosomes in Extremely Low Birth Weight Infants

Not yet recruiting NA Last updated 28 September 2022
What this trial tests

NA trial testing Exosomes derived from mesenchymal stromal cells (MSCs) in Premature Birth in 10 participants. Not yet recruiting.

Timeline
5 October 2022
Primary endpoint
22 May 2026
28 December 2026

Quick facts

Lead sponsorFederal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment10
Start date5 October 2022
Primary completion22 May 2026
Estimated completion28 December 2026
Sites1 location across Russia

Drugs / interventions tested

Conditions studied

Sponsor

Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare

Who can join

Adults 1 Day to 3 Days, any sex, with Premature Birth or Extreme Prematurity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To study the safety and efficacy of intranasal administration of exosomes derived from mesenchymal stromal cells on long-term neurodevelopmental outcome in extremely low birth weight infants born at gestational age 25/0-27/6 weeks.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Extracellular vesicles as tools and targets in therapy for diseases.
    Kumar MA, Baba SK, Sadida HQ, Marzooqi SA, et al · · 2024 · cited 686× · PMID 38311623 · DOI 10.1038/s41392-024-01735-1
  2. Clinical applications of stem cell-derived exosomes.
    Tan F, Li X, Wang Z, Li J, et al · · 2024 · cited 390× · PMID 38212307 · DOI 10.1038/s41392-023-01704-0
  3. New strategies of neurodegenerative disease treatment with extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs).
    Palanisamy CP, Pei J, Alugoju P, Anthikapalli NVA, et al · · 2023 · cited 86× · PMID 37554286 · DOI 10.7150/thno.83066
  4. Extracellular vesicles arising from apoptosis: forms, functions, and applications.
    Gregory CD, Rimmer MP. · · 2023 · cited 64× · PMID 37294158 · DOI 10.1002/path.6138
  5. Extracellular Vesicles as Therapeutic Resources in the Clinical Environment.
    Sanz-Ros J, Mas-Bargues C, Romero-García N, Huete-Acevedo J, et al · · 2023 · cited 53× · PMID 36768664 · DOI 10.3390/ijms24032344
  6. Extracellular vesicles set the stage for brain plasticity and recovery by multimodal signalling.
    Hermann DM, Peruzzotti-Jametti L, Giebel B, Pluchino S. · · 2024 · cited 45× · PMID 37768167 · DOI 10.1093/brain/awad332
  7. Advances in Therapies to Treat Neonatal Hypoxic-Ischemic Encephalopathy.
    Ranjan AK, Gulati A. · · 2023 · cited 41× · PMID 37892791 · DOI 10.3390/jcm12206653
  8. Insight into the Functional Dynamics and Challenges of Exosomes in Pharmaceutical Innovation and Precision Medicine.
    Sharma A, Yadav A, Nandy A, Ghatak S. · · 2024 · cited 40× · PMID 38931833 · DOI 10.3390/pharmaceutics16060709

Verify or expand the search:

Other recruiting trials for Premature Birth

Currently open trials in the same condition.

Other Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05490173.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing